1
|
|
2
|
Nilsson IM, Holmberg L, ÅBerg M, Vilhardt H. The Release of Plasminogen Activator and Factor VIII after Injection of DDAVP in Healthy Volunteers and in Patients with von Willebrand's Disease. ACTA ACUST UNITED AC 2009. [DOI: 10.1111/j.1600-0609.1980.tb02749.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
3
|
Ljung R, Holmberg L, Nilsson IM. Inheritable molecular variants of moderate and mild hemophilia A. ACTA MEDICA SCANDINAVICA 2009; 209:11-6. [PMID: 6782836 DOI: 10.1111/j.0954-6820.1981.tb11544.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Factor VIII clotting activity (VIII:C) and factor VIII clotting antigen (VIII:CAg) were investigated in 54 patients with hemophilia A of moderate or mild severity. The patients belonged to 28 kindreds. The study showed a genetically determined molecular variation within hemophilia A of both moderate and mild forms. Each form can be classified into 3 types according to the content of demonstrable VIII:CAg. Type I has no demonstrable VIII:CAg, type IIa has VIII:CAg in an amount smaller than, or approximately equal to, that of VIII:C and type IIb has a larger amount of VIII:CAg than VIII:C. Affected members of one and the same kindred always have the same type of the disease.
Collapse
|
4
|
Nilsson IM, Borge L, Gunnarsson M, Kristoffersson AC. Factor VIII related activities in concentrates. SCANDINAVIAN JOURNAL OF HAEMATOLOGY. SUPPLEMENTUM 2009; 41:157-72. [PMID: 6440282 DOI: 10.1111/j.1600-0609.1984.tb02776.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
5
|
Mikaelsson M, Nilsson IM, Cedergren B, Jonsson S, Rydberg L, Wiechel B. The use of desmopressin (DDAVP) in the preparation of improved factor VIII concentrate. SCANDINAVIAN JOURNAL OF HAEMATOLOGY. SUPPLEMENTUM 2009; 40:93-101. [PMID: 6433478 DOI: 10.1111/j.1600-0609.1984.tb02550.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
6
|
Nilsson IM, Vilhardt H, Holmberg L, Astedt B. Association between factor VIII related antigen and plasminogen activator. ACTA MEDICA SCANDINAVICA 2009; 211:105-12. [PMID: 6803518 DOI: 10.1111/j.0954-6820.1982.tb01909.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
7
|
Girma JP, Fressinaud E, Houllier A, Laurian Y, Amiral J, Meyer D. Assay of factor VIII antigen (VIII:CAg) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies. Haemophilia 1998; 4:98-103. [PMID: 9873846 DOI: 10.1046/j.1365-2516.1998.00149.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Monoclonal antibodies (MoAbs 833 and D4H1) directed against human factor VIII (FVIII) have been produced on a large scale to measure VIII:CAg by two-site ELISA (Asserachrom VIII:CAg, Diagnostica Stago). F(ab')2 from MoAb 833 were used for coating and bound VIII:CAg was revealed with MoAb D4H1 coupled to peroxidase. Control plasma (100 VIII:CAg U dL-1 by comparing with the International Standard) was used as reference. The assay sensitivity was 0.1 U dL-1 VIII:CAg. No apparent effect of the plasma proteins was observed provided plasma dilution was > or = 5. Thus this ELISA allowed us to estimate VIII:CAg levels of 0.5 U dL-1 in plasma. Levels of VIII:CAg were similar to those of VIII:C (correlation coefficient r = 0.87) in plasma from normal individuals (32 cases) and in patients with von Willebrand disease of various types (30 cases). Among 294 patients with haemophilia A (HA), 161 had severe HA (VIII:C < 1 U dL-1). Among those patients, 124 were cross-reacting material (CRM) negative with undetectable VIII:CAg and 37 were CRM+ (VIII:CAg 1-31 U dL-1). In 42 patients with moderate HA (VIII:C 1-5 U dL-1), 33 were CRM reduced (VIII:CAg 0.5-8 U dL-1) and nine were CRM+ with a VIII:CAg/VIII:C ratio of 6-91 (mean 34.3). In mild HA (91 cases with VIII:C > or = 6 U dL-1), 29 patients were classified as CRM+ (VIII:C 6-57 U dL-1, VIII:CAg 17-130 U dL-1 and VIII:CAg/VIII:C ratio 1.8-13.7 (mean 4.51)). In 62 CRM reduced patients there was a linear correlation between VIII:C (6-39 U dL-1) and VIII:CAg (2-36 U dL-1) levels (r = 0.88). In conclusion, this sensitive assay allows us to distinguish the quantitative CRM reduced and negative from the qualitative (CRM+) abnormalities in haemophilia A.
Collapse
Affiliation(s)
- J P Girma
- INSERM U.143, Hôpital de Bicêtre, Paris.
| | | | | | | | | | | |
Collapse
|
8
|
Hornsey VS, Drummond O, Eaglesfield P, Pepper DS, Prowse CV. Development, optimization and use of an enzyme linked immunosorbent assay (ELISA) to measure factor VIII antigen utilizing monoclonal antibodies. Transfus Med 1992; 2:223-9. [PMID: 1308833 DOI: 10.1111/j.1365-3148.1992.tb00159.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
An enzyme linked immunosorbent assay (ELISA) has been developed to measure VIII:Ag in plasma and concentrates. The assay utilizes two commercially available monoclonal antibodies to VIII:Ag and provides an alternative to the established immunoradiometric assay (IRMA). It has the advantage of not requiring the use of radioactive material and human antibodies. The assay sensitivity is 0.006 u/ml and the interassay coefficient of variation is 6.3%. Forty-eight samples with VIII:Ag levels ranging from 0.006 to 1.5 u/ml were assayed by both ELISA and IRMA. The coefficient of correlation between the two assays was 0.89. In addition to measuring human VIII:Ag, it is also possible to detect antigen in several animal plasma and sera.
Collapse
Affiliation(s)
- V S Hornsey
- Scottish National Blood Transfusion Service, National Science Laboratory, Edinburgh
| | | | | | | | | |
Collapse
|
9
|
Tedgård, Ljung R, McNeil T, Tedgård E, Schẃartz M. How do carriers of hemophilia experience prenatal diagnosis (PND)? Carriers' Immediate and later reactions to amniocentesis and fetal blood sampling. ACTA PAEDIATRICA SCANDINAVICA 1989; 78:692-700. [PMID: 2596275 DOI: 10.1111/j.1651-2227.1989.tb11128.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A semistructured personal interview was performed with 29 carriers of hemophilia A or B, 1-5 years after a pregnancy in which prenatal diagnosis (PND) was performed by fetal blood sampling. Fetal blood sampling by fetoscopy was significantly more often reported by the women to the more trying than expected than was ultrasound-guided heart puncture. Of 29 women 13 was classified as having experienced the PND process (amniocentesis and fetal blood sampling) as distressing, having had mental or psychosomatic symptoms associated with it. All of the women who had abortion/miscarriage after PND reported a very high frequency of psychological sequelae during the 6 months that followed PND. Of 22 women who continued their pregnancy with a healthy fetus after PND 8 experienced the period until delivery as trying and felt that their emotional and somatic status influenced their daily life activities. This was particularly common among women who after fetoscopy received routine profylactic terbutalin treatment and had continuous sickleave until the 36th gestational week, 17/29 would consider going through PND in the future. Qualified psychological assistance must be offered both before and after PND.
Collapse
Affiliation(s)
- Tedgård
- Department of Pediatrics, University of Lund, Malmö, General Hospital, Sweden
| | | | | | | | | |
Collapse
|
10
|
Arai M, Inaba H, Higuchi M, Antonarakis SE, Kazazian HH, Fujimaki M, Hoyer LW. Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine). Proc Natl Acad Sci U S A 1989; 86:4277-81. [PMID: 2498882 PMCID: PMC287434 DOI: 10.1073/pnas.86.11.4277] [Citation(s) in RCA: 57] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
An immunoadsorbent method has been developed for the direct analysis of normal and variant plasma factor VIII. Using this method, the molecular defect responsible for mild hemophilia A has been identified for a patient whose plasma factor VIII activity is 0.05 unit/ml, even though the factor VIII antigen content is 3.25 units/ml. Although the variant factor VIII has an apparently normal molecular mass and chain composition, the 92-kDa heavy chain accumulates when the variant protein is incubated with thrombin and the 44-kDa heavy chain fragment cannot be detected. In contrast, thrombin cleavage of the 80-kDa light chain to the 72-kDa fragment is normal. As these data indicate a loss of factor VIII cleavage by thrombin at arginine-372, the genetic defect was determined by polymerase-chain-reaction amplification of exon 8 of the factor VIII gene and direct sequencing of the amplified product. A single-base substitution (guanine----adenine) was identified that produces an arginine to histidine substitution at amino acid residue 372. These data identify the molecular basis of an abnormal factor VIII, "factor VIII-Kumamoto," that lacks procoagulant function because of impaired thrombin activation.
Collapse
Affiliation(s)
- M Arai
- Holland Laboratory, American Red Cross, Rockville, MD 20855
| | | | | | | | | | | | | |
Collapse
|
11
|
Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318:947-50. [PMID: 3127711 DOI: 10.1056/nejm198804143181503] [Citation(s) in RCA: 222] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The development of antibodies to factor VIII is a serious complication of the treatment of patients with hemophilia A. We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined factor VIII, cyclophosphamide, and high-dose intravenous IgG, followed by regular prophylactic treatment with factor VIII. This protocol has now been used in 11 patients with hemophilia A, of whom 9 had a strong antibody response. When the initial concentration of antibodies exceeded 3 Malmö inhibitor units (corresponding to about 10 Bethesda units) per milliliter, treatment was preceded by adsorption of antibody to protein A. After two to three weeks of the combined treatment, factor VIII coagulant antibodies had disappeared in 9 of the 11 patients; in 8 of these 9 patients the half-life of infused factor VIII had normalized. The tolerant state appears to be stable after a median of 30 months. Two patients did not respond to the treatment. Because earlier treatment with factor VIII and cyclophosphamide or with factor VIII and IgG had been ineffective in these patients, our experience suggests that all three components of the protocol are required for the successful induction of tolerance to factor VIII.
Collapse
Affiliation(s)
- I M Nilsson
- Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Sweden
| | | | | |
Collapse
|
12
|
Nordfang O, Ezban M, Nilsson P, Knudsen JB. Radioimmunoassay for quantitative measurement of factor VIII-heavy chain. Br J Haematol 1988; 68:307-12. [PMID: 3128321 DOI: 10.1111/j.1365-2141.1988.tb04207.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
An immunoassay has been developed for the measurement of factor VIII heavy chain (FVIII-HC). IgG from a human inhibitor plasma with specificity for FVIII-HC and FVIII-light chain (FVIII-LC) was coated to microplates with loose wells. After washing, the plates were incubated with sample and after another wash 125I-FVIII-HC was added so that the amount of bound tracer was dependent on the amount of FVIII-HC in sample. When EDTA was included in the assay buffer the assay response was increased 3-fold for normal human plasma. This indicated that the antibody was reactive with a determinant hidden in the FVIII-HC/FVIII-LC complex as EDTA splits the complex. The sensitivity of the assay was 0.004 units/ml (1 unit/ml in normal human plasma pool). Together with a previously published assay for FVIII-LC it has now become possible to measure the relative amounts of FVIII-HC and FVIII-LC in haemophilia A plasma and to study the separate expression of FVIII-HC and FVIII-LC by recombinant DNA technology. Patients with severe haemophilia A had FVIII-HC levels below 0.01 units/ml. However, inhibitor patients in high dose FVIII-treatment showed up to 50 times higher levels of FVIII-HC than FVIII-LC and FVIII:C, indicating the presence of FVIII/anti-FVIII-LC immune complexes. Thus, dependent on assay specificity plasma samples can show very variable content of FVIII:antigen.
Collapse
|
13
|
Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Eur J Haematol 1988; 40:205-14. [PMID: 3128452 DOI: 10.1111/j.1600-0609.1988.tb00825.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The following commercial virus-inactivated factor VIII concentrates were studied in vitro: AHF-Kabi and Octonativ, KabiVitrum; Hemofil T, Hyland; Factorate HP and Monoclate, Armour; Nordiocto, Nordisk Gentofte (dry heated); Kryobulin TIM3, Immuno (steam treated); Profilate, Alpha (heated as dry material slammed in heptane); Hemate P, Behring (wet heated) and Octa-V.I., Octapharma (solvent/detergent treated). The concentration of VIII:C was lowest in AHF-Kabi, whereas it ranged from 24 to 53 IU/ml in the high purity concentrates, except for Monoclate in which it ranged from 91-128 IU/ml. All concentrates but Octa-V.I. had higher values for VIII:Ag than for VIII:C. von Willebrand factor with normal distribution of multimers could only be demonstrated in AHF-Kabi and Hemate P. In vivo studies were performed in 12 severe hemophiliacs. Recovery and half-life of VIII:C did not differ between the various concentrates. Hemate P was given to 5 patients with severe von Willebrand's disease, in all of whom a correction of the hemostatic defect was seen.
Collapse
Affiliation(s)
- E Berntorp
- Department for Coagulation Disorders, Malmö General Hospital, Sweden
| | | |
Collapse
|
14
|
Ljung R, Tedgård U, McNeil T, Tedgård E. How do carriers of hemophilia experience prenatal diagnosis by fetal blood sampling? Clin Genet 1987; 31:297-302. [PMID: 3608215 DOI: 10.1111/j.1399-0004.1987.tb02811.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
A semistructured personal interview was performed with 29 carriers of hemophilia A or B, 1-4 years after a pregnancy in which prenatal diagnosis (PND) of hemophilia was performed by fetal blood sampling. The carriers had received different recommendations regarding future pregnancies, and 14/29 did not know before they became pregnant that PND by fetal blood sampling was possible. One third of the women felt that important information was lacking in the consultations that preceded the PND. The conclusions regarding future genetic counselling are that more attention should be paid to improving education of all female carriers before a pregnancy, to motivating fathers-to-be to attend counselling sessions with the carriers, and to emphasizing the importance of the emotional support given by the family doctor and by other females who have experienced PND.
Collapse
|
15
|
Abstract
Factor VIII is a large procoagulant glycoprotein that circulates in plasma in a noncovalent complex with von Willebrand factor. It is essential for the efficient cleavage of coagulation factor X by factor IXa, and its absence causes a severe bleeding disorder. Plasma factor VIII is reduced from the normal range of approximately 100 to 200 ng/ml in patients with the hereditary coagulation defect, hemophilia A, as well as in patients who develop autoantibodies that inactivate factor VIII. The understanding of factor VIII structure has been enhanced by recent studies that have characterized the X chromosome gene responsible for its synthesis, and preliminary information is now available about specific genetic defects. The basis for antibody formation in approximately 15 per cent of repeatedly transfused hemophilic patients is less clear at this time, however, for these individuals appear to have a variety of genetic defects that are not characteristically different from the patients who do not develop inhibitors. Although the antibodies cause a serious problem for affected individuals, they have been very useful in characterizing normal factor VIII and nonfunctional factor VIII-like protein that is found in the plasmas of 10 per cent of patients with mild hemophilia. Moreover, they are very useful reagents that can be used for immunoassay of factor VIII that has been modified in ways that have destroyed its procoagulant function.
Collapse
|
16
|
Lethagen S, Ostergaard H, Nilsson IM. Clinical application of the chromogenic assay of factor VIII in haemophilia A, and different variants of von Willebrand's disease. SCANDINAVIAN JOURNAL OF HAEMATOLOGY 1986; 37:448-53. [PMID: 3101169 DOI: 10.1111/j.1600-0609.1986.tb02636.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
A chromogenic substrate kit for determination of factor VIII activity (COATEST Factor VIII) was compared to a one-stage clotting assay and the correlation was evaluated in different genetic variants of mild and moderate haemophilia A, in severe haemophilia A and in all known variants of von Willebrand's disease. In all these cases a high correlation between the two methods was obtained. A good correlation was also obtained after intranasal administration of DDAVP (1-desamino-8-D-arginine vasopressin) to patients with von Willebrand's disease. The chromogenic substrate method was performed using a microtray technique.
Collapse
|
17
|
Andersson LO, Forsman N, Huang K, Larsen K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J. Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc Natl Acad Sci U S A 1986; 83:2979-83. [PMID: 3085106 PMCID: PMC323430 DOI: 10.1073/pnas.83.9.2979] [Citation(s) in RCA: 106] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Human factor VIII has been isolated from a high purity factor VIII concentrate by immunoaffinity chromatography and HPLC on Mono Q gel. Two fractions of factor VIII were obtained with a specific activity of approximately equal to 7000 units/mg. The major fraction contained eight peptide chains of 200, 180, 160, 150, 135, 130, 115, and 105 kDa plus one doublet chain of 80 kDa. The minor fraction contained one peptide chain of 90 kDa plus the chain of 80 kDa. Both fractions were activated by thrombin to the same extent. Amino-terminal amino acid sequence analysis was performed on the 180-kDa, 130-kDa, and 90-kDa chains and showed an identical amino-terminal sequence in these chains. Each chain from 200 kDa to 90 kDa was linked to one 80-kDa chain by a metal-ion bridge(s). Studies on factor VIII in plasma and cryoprecipitate, prepared and gel filtered in the presence of protease inhibitors, showed that one 200-kDa plus one 80-kDa chain were the only or dominating chains in the materials and may represent native factor VIII. The results indicated that all chains from 180 kDa to 90 kDa are fragments of the 200-kDa chain. All of these more or less fragmented chains form active factor VIII complexes with the 80-kDa chain.
Collapse
|
18
|
Colman RW, Budzynski AZ. Blood Coagulation and Fibrinolysis. Compr Physiol 1985. [DOI: 10.1002/cphy.cp030116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
19
|
Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752-6. [PMID: 3936044 PMCID: PMC391515 DOI: 10.1073/pnas.82.24.8752] [Citation(s) in RCA: 123] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
The procoagulant protein F.VIII:C is noncovalently bound to von Willebrand factor (vWF) to give the factor VIII macromolecular complex. New highly purified preparations of isolated human F.VIII:C, devoid of vWF and about 500,000-fold purified, were administered to hemophilia A and von Willebrand disease (vWD) dogs to determine their hemostatic effectiveness and survival in the circulation. Two preparations of F.VIII:C were used: peak 1, with active components of Mr 185,000-280,000, and peak 2, with a single component of Mr 170,000. In hemophilic dogs, with no plasma F.VIII:C but normal vWF, both preparations immediately elevated plasma F.VIII:C to expected levels, promptly stopped induced and spontaneous hemorrhages, and gave sustained plasma levels of F.VIII:C. The isolated F.VIII:C immediately complexed with endogenous vWF in hemophilic plasma and was eliminated exponentially, with a half-life (t1/2) of about 9 hr. Survival of peak 2 F.VIII:C was longer than that of peak 1 material. In contrast, F.VIII:C complexed to vWF in a therapeutic concentrate administered to hemophilic dogs was eliminated biexponentially with first-phase t1/2 of 3.2 hr and second-phase t1/2 of 9 hr. In vWD dogs with no vWF and reduced F.VIII:C levels, the isolated F.VIII:C produced supernormal levels of F.VIII:C without effect on induced bleeding. It was rapidly eliminated from plasma with a t1/2 of about 1 hr, as was the complexed F.VIII:C in the concentrate. These data indicate that isolated F.VIII:C promptly complexes with vWF and in this form is highly effective in controlling hemophilic hemorrhages with good survival in plasma. Without endogenous vWF with which to complex, the F.VIII:C is promptly eliminated.
Collapse
|
20
|
Kobayashi I, Lamme S, Nilsson IM. The interaction between factor VIII clotting antigen and phospholipids in genetic variants of hemophilia and von Willebrand's disease. Thromb Res 1984; 35:65-75. [PMID: 6433504 DOI: 10.1016/0049-3848(84)90313-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The interaction of factor VIII with phospholipids was investigated in 11 patients with mild and moderate hemophilia A, 7 patients with von Willebrand's disease and in 10 healthy people as controls. The addition of phospholipid vesicles containing phosphatidylserine and phosphatidylethanolamine to normal plasma and that of patients with von Willebrand's disease resulted in the loss of almost two thirds of the factor VIII clotting antigen (VIII:CAg) measurable by IRMA. Defective interaction of phospholipids with VIII:CAg was noted in some genetic variants of mild and moderate hemophilia A. Thus four of the five families tested showed decreased binding of VIII:CAg to phospholipids. One of the families tested belonged to a genetic variant with much more VIII:CAg than VIII:C, and it was in members of this family that the binding capacity was most reduced. The most probable explanations for the defective interaction with phospholipids is that molecular defects of VIII:CAg result in either decreased binding to phospholipids or might lead to a stronger binding between VIII:CAg and the von Willebrand factor (VIIIR:Ag) in the factor VIII complex and thereby preventing the normal separation of the complex.
Collapse
|
21
|
Application of Immunologic Assays to the Coagulation Laboratory. Clin Lab Med 1984. [DOI: 10.1016/s0272-2712(18)30932-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
22
|
Veerman EC, Stel HV, Huisman JG, van Mourik JA. Application of sepharose-linked monoclonal antibodies for the immunoradiometric measurement of factor VIII-procoagulant antigen. Thromb Res 1984; 33:89-93. [PMID: 6420931 DOI: 10.1016/0049-3848(84)90157-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
23
|
Exner T, Rickard KA, Kronenberg H. Measurement of factor VIII CAg by immunoradiometric assay in human tissue extracts. Thromb Res 1983; 32:427-36. [PMID: 6419382 DOI: 10.1016/0049-3848(83)90094-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Samples of normal tissues taken from three patients within 24 hours of death were physically disrupted, washed and extracted. Centrifuged supernatants were tested for factor VIII coagulant antigen (VIII CAg) and factor VIII related antigen (VIII RAg) by radioimmunoassays using homologous and heterologous antisera respectively. VIII RAg was readily washed out by isotonic saline whereas VIII CAg required 1.5 M sodium chloride for optimal extraction from tissue homogenates. Highest levels of VIII CAg were detected in some lymph nodes followed by lung, liver and spleen. There was rapid loss of VIII CAg from most tissues in the absence of proteolytic inhibitors.
Collapse
|
24
|
Rock G, Ganz P, Tackaberry E. The relationship of biological and immunological activities of factor VIII. Biochem Biophys Res Commun 1983; 115:981-7. [PMID: 6194798 DOI: 10.1016/s0006-291x(83)80031-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Factor VIII is an essential blood clotting factor which consists of two protein moieties, each with distinct biological functions and antigenic determinants. The immunological markers were originally seen as indicators of the biological activities; however this view has been increasingly challenged. We have investigated the biological and immunological properties of Factor VIII to clarify these relationships. Plasma stored at room temperature for 21 days lost biological activity, but retained immunological activity: The procoagulant activity was reduced to 35% and the ristocetin cofactor activity to 75.4% of their original levels; but the reactivities of both procoagulant antigen and Factor VIII related antigen were maintained. A dissociation of activities was also demonstrated in serum, in which the procoagulant activity was 10% and the procoagulant antigen 72% of corresponding plasma values. These results indicate that the antigenic reactivities are not appropriate markers for Factor VIII biological activity.
Collapse
|
25
|
Dinesen B, Feddersen C. An enzyme immunoassay (ELISA) for the quantitation of human factor VIII coagulant antigen (VIII:CAg). Thromb Res 1983; 31:707-18. [PMID: 6417826 DOI: 10.1016/0049-3848(83)90101-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
For the purposes of prenatal diagnosis and carrier detection of haemophilia A, an enzyme linked immunosorbent assay (ELISA) was developed for the quantitation of plasma Factor VIII coagulant antigen (VIII:CAg). It is based upon a human antibody. Results are compared to assays for Factor VIII coagulant activity (VIII:C) and Factor VIII related antigen (VIIIR:Ag) in plasma from 30 normal female individuals, 5 fetuses from mothers normal with respect to bleeding status, 10 obligate carriers of haemophilia A, 10 patients with haemophilia A, 5 with von Willebrand's disease, and 5 with haemophilia B. The ELISA developed is simpler than previously published VIII:CAg methods owing to its use of total IgG instead of immunologically affinity-purified antibodies. It is specific (as judged from clinical results), sensitive (detection limit: 0.005 units/ml), and sufficiently precise (between-assay coefficient of variation: 11%) for the purposes mentioned. The coefficient of correlation between VIII:CAg and VIII:C results is 0.86. The introduction of ELISA for quantitating VIII:CAg represents an advantage as compared to existing immunoradiometric assays (IRMA) mainly due to the stable and non-radioactive reagents used in the ELISA.
Collapse
|
26
|
Abstract
The efficacy of high purity preparations of factor VIII complex are usually lacking effect on the bleeding time in von Willebrand's disease. In this report we have studied the efficacy of a new high purity factor VIII preparation in two von Willebrand and two hemophilia A patients. The prolonged bleeding time in the patients with von Willebrand's disease was corrected after infusion of the preparation and a secondary rise in factor VIII procoagulant activity (VIII:C) demonstrated. The biological half-life time of VIII:C, in the two hemophilia A patients, was about 15 hrs. The investigation shows that this particular preparation is capable of correcting the prolonged bleeding time in von Willebrand's disease.
Collapse
|
27
|
Abstract
The effects of various concentrations of plasmin and activated protein C on the factor VIII procoagulant activity (VIII:C) and coagulant antigen (VIII:CAg) were studied in factor VIII concentrates and normal plasma. Small amounts (0.1 CTA U/ml) of plasmin rapidly destroyed VIII:C, and affected, but did not destroy VIII:CAg, in factor VIII concentrates. In normal plasma larger amounts of plasmin (1.8 CTA U/ml) was required to inactivate VIII:C in order to exceed the neutralizing capacity of alpha 2-antiplasmin. VIII:CAg was unchanged indicating a limited proteolysis. The difference between VIII:C and VIII:CAg was found also in urokinase-activated plasma. Activated protein C (5 micrograms/ml), in the presence of Ca2+ and phospholipids, inactivated VIII:C without affecting VIII:CAg in a high purity factor VIII concentrate. Higher concentrations of activated protein C (25 micrograms/ml) caused a slight decrease of VIII:CAg, even in the absence of Ca2+ and phospholipids, but did not change VIII:CAg in normal plasma or serum.
Collapse
|
28
|
Furlong RA, Peake IR. Studies on the stability of factor VIII coagulant antigen (VIII:CAg) in the presence of VIII:C antibodies. Br J Haematol 1983; 53:55-63. [PMID: 6401211 DOI: 10.1111/j.1365-2141.1983.tb01986.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The stability of factor VIII coagulant antigens (VIII:CAg) at 56 degrees C was investigated using an immunoradiometric assay for VIII:CAg. In normal or CRM+ haemophilic plasmas VIII:CAg was rapidly inactivated at 56 degrees C. VIII:CAg in spontaneous VIII:C inhibitor plasmas and in post-treatment samples from haemophiliacs with VIII:C inhibitor was resistant to inactivation at 56 degrees C, indicating the presence of heat stable VIII:CAg-anti VIII:CAg complexes. In vitro VIII:CAg-anti VIII:CAg complexes were formed by incubation of diluted VIII:C antibodies and normal plasma and the stability of these complexes at 56 degrees C was studied. Haemophilic VIII:CAg antibodies formed heat stable immune complexes over a narrow range of inhibitor dilutions whilst some spontaneous VIII:CAg antibodies formed these stable complexes over a much wider range of dilutions emphasizing the difference in the properties of these antibodies.
Collapse
|
29
|
Canfield WM, Kisiel W. Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease. J Clin Invest 1982; 70:1260-72. [PMID: 6294139 PMCID: PMC370343 DOI: 10.1172/jci110725] [Citation(s) in RCA: 62] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Human activated protein C (APC) is a plasma serine protease that possesses amidolytic and anticoagulant activity. The rate at which the amidolytic and anticoagulant activity of APC was neutralized in normal plasma was essentially identical to that observed in plasma obtained from four individuals with combined Factor V/VIII deficiency disease. Incubation of radioiodinated APC with either normal human plasma or the combined Factor V/VIII-deficient plasmas resulted in the formation of a stable complex (Mr = 96,000) of the enzyme and a plasma protein as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Pretreatment of the radiolabeled APC with diisopropyl fluorophosphate prevented the formation of the enzyme-protein complex. On the basis of its ability to form a complex with radiolabeled APC, the APC-binding protein was purified to homogeneity from normal human plasma by ammonium sulfate fractionation, heparin-agarose chromatography, and QAE-Sephadex A-50 chromatography. The APC-binding protein (Mr = 54,000) is a glycoprotein, and possesses an amino-terminal sequence of Gly-Arg-Thr-Cys-Pro-Lys-Pro-Asp. The amino-terminal sequence of the APC-binding protein exhibited considerable homology with bovine colostrum inhibitor and pancreatic trypsin inhibitor, but no apparent sequence homology with the plasma serine protease inhibitors. Affinity-purified antibody against APC-binding protein immunoprecipitated a complex of radiolabeled APC and native APC-binding protein from normal human plasma. Complex formation was virtually eliminated in plasma immunodepleted of the APC-binding protein. Quantitative electroimmunoassay indicated essentially equal levels of APC-binding protein antigen in normal plasma compared with plasma from four patients with combined Factor V/VIII deficiency disease.
Collapse
|
30
|
Harmon JT, Jamieson GA, Rock GA. The functional molecular weights of factor VIII activities in whole plasma as determined by electron irradiation. J Biol Chem 1982. [DOI: 10.1016/s0021-9258(19)45372-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
31
|
Muller HP, van Tilburg NH, Bertina RM, Veltkamp JJ. Heterogeneity of haemophilia A: a study with three different antisera. Br J Haematol 1982; 52:485-94. [PMID: 6812615 DOI: 10.1111/j.1365-2141.1982.tb03918.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
One human and one rabbit antibody against VIII:C--in a fluid-phase, inhibitor neutralization assay (INA)--and one human antibody--in a solid-phase, immunoradiometric assay (IRMA)--were used to investigate a group of 59 patients with severe, moderate and mild haemophilia A. Patients were classified as haemophilia A+ when the VIII:C/VIIIAG ratio was less than 0.4 while the absolute VIII:C antigen (VIIICAG) value exceeded 0.25 u/ml. Three haemophiliacs (from two pedigrees) were classified as A+ in all three assay systems. 50% of the patients were classified as haemophilia A+ on the basis of at least one assay. The other 50%, including 66% of the patients with severe haemophilia, were shown to be A- by all three assay systems. Combining the data obtained with the three different antibodies four different categories could be distinguished, in addition to the classification based on severity.
Collapse
|
32
|
Ljung R, Holmberg L. Immunoradiometric assay of inhibitors of antihaemophilic factor A. ACTA PAEDIATRICA SCANDINAVICA 1982; 71:1019-23. [PMID: 6818831 DOI: 10.1111/j.1651-2227.1982.tb09566.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
An immunoradiometric assay (IRMA) for determination of antibodies against f. VIII:C in haemophilia A was developed. The assay was based on competitive binding of radiolabelled anti-VIII:C and antibodies in the test material to immobilized VIII:C. Fifteen haemophiliacs with known inhibitors were investigated with the new method and with a conventional neutralization test. In 3 cases the inhibitors were detected only with the IRMA and in the other 12 there was good agreement between the inhibitor levels found with the two methods. It was also possible to demonstrate the antibodies in three non-haemophilic patients with acquired inhibitors. The IRMA, which can detect the antibodies down to a concentration of 0.02 inhibitor units per ml, is more sensitive than conventional neutralization tests and is thus of practical importance in the investigation of patients with low inhibitor titres.
Collapse
|
33
|
Thomas KB, Howard MA, Koutts J, Firkin BG. Simplified immunoradiometric assay for factor VIII coagulant antigen. Br J Haematol 1982; 51:47-57. [PMID: 6803825 DOI: 10.1111/j.1365-2141.1982.tb07288.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A simplified, non-competitive, solid phase immunoradiometric assay has been developed for the quantitation of factor VIII coagulant antigen (VIII:CAg)--the antigenic counterpart of FVIII coagulant activity (VIII:C). Both homologous and heterologous antibodies to human factor VIII (FVIII) were used in this assay. Initially, FVIII in a test sample was attached to immobilized, human IgG obtained from a polytransfused haemophilia A patient with a high titre antibody to VIII:C. The bound FVIII was then detected using rabbit 125I-IgG specific for human FVIII. The concentration of VIII:CAg correlated well with VIII:C levels in the plasma from normal donors (r = 0.84, n - 15). Homozygote von Willebrand's disease patients had undetectable levels of VIII:CAg in their plasma. Patients with severe haemophilia A (VIII:C less than 0.01 u/ml) could be divided into groups on the basis of the VIII:CAg levels, i.e. those having undetectable VIII:CAg and other with measurable VIII:CAg. VIII:CAg detected in normal serum was less than 0.002 u/ml. In this assay the use of human antibody to FVIII is considerably decreased compared to other methods for VIII:CAg, and the time-consuming steps to immunopurify human anti-FVIII antibody are eliminated.
Collapse
|
34
|
McLellan DS, Pelly C, McLellan HG, Jones P, Aronstam A. The 'in vivo' survival characteristics of factor VIII procoagulant antigen (VIII:C Ag) in haemophilia A subjects. Thromb Res 1982; 25:33-9. [PMID: 6801811 DOI: 10.1016/0049-3848(82)90212-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Initial half disappearance times and biological half-lives were determined for factor VIII procoagulant antigen (VIII:C Ag) and compared with VIII procoagulant (VIII:C) survival for each of two commercial concentrates, transfused into seven severe (less than 1 i.u./dl) non-bleeding haemophiliacs. The results show that VIII:C Ag has similar half disappearance and biological half-life to that of factor VIII:C. The relevance of these results to recently published findings is discussed.
Collapse
|
35
|
Lavergne JM, Meyer D, Girma JP, Larrieu MJ. Precipitating anti-VIII:C antibodies in two patients with haemophilia A. Br J Haematol 1982; 50:135-46. [PMID: 6798988 DOI: 10.1111/j.1365-2141.1982.tb01898.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
IgG from the plasmas of two haemophilia A patients with anti-VIII:CAg antibodies (1000 and 200 u/ml) was isolated and labelled with 125I. The specific labelled anti-VIII:CAg IgG was further purified by binding to and elution from immobilized factor VIII/von Willebrand factor (F.VIII/vWF). When studied by immunodiffusion and autoradiography, both antibodies gave a precipitin line with normal plasma, serum, cryoprecipitate, purified F.VIII/vWF and the plasmas of two patients with haemophilia A+. No precipitin line was observed with the plasmas of 11 patients with haemophilia A- or four patients with severe von Willebrand's disease. Levels of VIII:CAg obtained by radioelectroimmunoassay were in agreement with those obtained by immunoradiometric assay. This study demonstrates that, contrary to previous evidence, human anti-VIII:CAg antibodies are precipitating as well as neutralizing when studied by highly sensitive techniques.
Collapse
|
36
|
Ljung R, Holmberg L. F VIII:CAg in Haemophilia A. A comparison between IRMA:s using haemophilic and spontaneous antibodies. Thromb Res 1981; 24:45-50. [PMID: 6800058 DOI: 10.1016/0049-3848(81)90030-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
37
|
Furlong RA, Peake IR, Bloom AL. Factor VIII clotting antigen (VIIICAg) in haemophilia measured by two immunoradiometric assays (IRMA) using different antibodies, and the measurement of inhibitors to procoagulant factor VIII (VIIIC) by IRMA. Br J Haematol 1981; 48:643-50. [PMID: 6791678 DOI: 10.1111/j.1365-2141.1981.00643.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Factor VIII clotting antigen (VIIICAg) was measured by immunoradiometric assay (IRMA) using two different antibodies. Both antibodies arose in polytransfused severe haemophiliacs and had similar titres against VIIIC. In 12 normal plasmas there was no significant difference in VIIICAg values obtained (VIIICAg (AbI) = VIIICAg (AbII)). In the majority of 15 severe haemophiliacs tested VIIICAg was undetectable by both antibodies. In 28 mild to moderate haemophiliacs VIIICAg (AbII) was significantly greater than VIIICAg (AbI) (P less than 0.01) suggesting different antigenic determinants. The difference, however, was small and does not affect diagnosis of haemophilia. A modified IRMA has been used to measure anti VIIIC inhibitors by competition of the inhibitor with 125I labelled VIIICAg antibodies for common antigenic determinants. Using an inhibitor of 225 Bethesda units as a standard, results by IRMA of inhibitors in severe haemophiliacs have been similar to those obtained by clotting assay, but with a sensitivity of 0.01 u/ml suggesting the possible use in the detection of weak inhibitors.
Collapse
|
38
|
Holmberg L, Borge L, Nilsson IM. Factor VIII:C and VIII:CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma. Br J Haematol 1981; 47:587-96. [PMID: 6783063 DOI: 10.1111/j.1365-2141.1981.tb02688.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Factor VIII procoagulant activity (VIII:C) and factor VIII procoagulant antigen (VIII:CAg) were studied in seven patients with haemophilia A after administration of three different factor VIII concentrates or plasma. The in vivo recovery of VIII:CAg was less than that of VIII:C and the disappearance rate of VIII:CAg was much higher either when concentrates or plasma were given. The half-life of VIII:C was thus about 12 h but of VIII:CAg only about 3 h or less. Six patients with von Willebrand's disease were studied after administration of AHF-Kabi. In contrast to haemophilia A the discrepancy between VIII:C and VIII:CAg disappearance rates was not present in von Willebrand's disease, since both VIII:C and VIII:CAg showed a typical progressive increase. We conclude that factor VIII:C given to haemophilia patients does not behave like native VIII:C, not even when fresh plasma is used. Patients with von Willebrand's disease are capable of forming a normal VIII:C when appropriately stimulated.
Collapse
|
39
|
Rotblat F, Tuddenham EG. Immunologic studies of factor VIII coagulant activity (VIII:C) 1. Assays based on a haemophilic and an acquired antibody to VIII:C. Thromb Res 1981; 21:431-45. [PMID: 6791294 DOI: 10.1016/0049-3848(81)90144-4] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
40
|
Girma JP, Lavergne JM, Meyer D, Larrieu MJ. Immunoradiometric assay of factor VIII: coagulant antigen using four human antibodies. Study of 27 cases of haemophilia A. Br J Haematol 1981; 47:269-82. [PMID: 6781526 DOI: 10.1111/j.1365-2141.1981.tb02788.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Immunoradiometric assay (IRMA) of VIII:C antigen was performed using either IgG or monovalent Fab fragments from four antibodies arisen in polytransfused haemophilia A patients (titre between 100 and 1500 U/ml). Using IgG isolated by a solid or a liquid phase system, only the high titre (greater than or equal to 1000 U/ml) antibodies could be used for IRMA, with a sensitivity of 0.2% VIII:CAg. Using Fab fragments isolated by liquid phase, high and low (less than or equal to 150 U/ml) titre antibodies could be used and the IRMA was significantly improved with a 10-fold higher sensitivity. The affinity of the antibodies for VIII:CAg, studied by displacement curves using a modification of the IRMA, was found not to depend upon the titre of the antibody. Comparative levels of VIII:C and VIII:CAg in 27 cases of haemophilia A emphasize the heterogeneity of this disorder, two types of severe and three types of mild haemophilia being observed.
Collapse
|
41
|
Abstract
Recent advances in the elucidation of the molecular biochemistry of the coagulation proteins have provided the foundation for the development of synthetic substrates. These substrates are oligopeptide with either a chromophore or fluorophore group attached to the C-terminal end. They may be used in the laboratory to assay for a number of the serine proteases involved in either coagulation or fibrinolysis. Also, by suitably modifying the assay system, the various inhibitors can be quantitated. These substrates promise to revolutionize the coagulation laboratory allowing for more precise quantitation of trace enzymes and also improved standardization and precision of coagulation assays. In addition to these substrates, the introduction of a number of immunologic procedures into the diagnostic laboratory have been of major importance in elucidating the heterogeneity of hereditary coagulation defects. By correlating the immunologic assays, coagulation assays and clinical picture, a number of subgroups of hereditary deficiencies have been identified. Also, the immunologic assays have provided a means for identifying the carrier state of hemophilia A and have significantly contributed to the improved diagnosis of von Willebrand's disease. The use of ristocetin cofactor assays, when used in conjunction with the Factor VIII antigens, have enable the laboratory to more accurately diagnose the majority of patients with von Willebrand's disease. Ristocetin cofactor may be assayed utilizing either formalin fixed or washed platelets and recently a snake venom has been introduced to assay for this particular aspect of the Factor VIII complex. Platelet specific proteins (i.e., platelet factor 4 and beta-thromboglobulin) may be assayed utilizing either radioimmunoassays or in the case of platelet factor 4 modified coagulation assays. These proteins provide evidence of in vivo platelet activation and hopefully may, in the future, be correlated with platelet kinetics.
Collapse
|
42
|
|
43
|
Muller HP, van Tilburg NH, Bertina RM, Terwiel JP, Veltkamp JJ. Immunoradiometric assay of procoagulant factor VIII antigen (VIIICAG). Clin Chim Acta 1980; 107:11-9. [PMID: 6775848 DOI: 10.1016/0009-8981(80)90408-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
An immunoradiometric assay of procoagulant factor VIII antigen was developed using a human antibody to the procoagulant activity of factor VIII (VIII:C). The assay measures specifically the antigen related to factor VIII procoagulant activity (VIIICAG) both in plasma and in serum. VIII:C and VIIICAG were measured in a group of healthy individuals and in a group of haemophilia A patients. In haemophilia A at least four groups can be recognised on the basis of the presence or absence of VIII:C and VIIICAG and the VIII:C/VIIICAG ratio.
Collapse
|
44
|
Nilsson IM, Holmberg L, Stenberg P, Henriksson P. Characteristics of the factor VIII protein and Factor XIII in various factor VIII concentrates. SCANDINAVIAN JOURNAL OF HAEMATOLOGY 1980; 24:340-9. [PMID: 6774412 DOI: 10.1111/j.1600-0609.1980.tb01593.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The in vitro properties of 5 factor VIII preparations (AHF-Kabi, Hemofil Hyland, AHF-Profilate Abbott, Kryobulin Immuno and Factorate High Purity Armour) and an ordinary cryoprecipitate were studied with reference to factor VIII clotting activity (VIII:C), factor VIII clotting antigen (VIII:CAg), factor VIII related antigen (VIIIR:Ag) (EI, IRMA, CIE), ristocetin cofactor activity (VIIIR:RCF), fibrinogen and factor XIII. All the preparations with the exception of Factorate had higher levels of VIII:CAg than VIII:C indicating inactivation of the biological activity of VIII:C during the procedure. AHF-Kabi (fraction I-0) and the cryoprecipitate, the only preparations capable of normalising the defect in patients with von Willebrand's disease, showed the same level of VIIIR:Ag determined by EI and by IRMA, while all the other preparations (i.e. cryoprecipitates purified further in different ways) had considerably lower levels of VIIIR:Ag determined by IRMA than by EI. Based on these in vitro techniques it seems to be possible to predict which preparations can be used successfully in patients with von Willebrand's disease, while no such conclusions can be made from VIIIR:RCF determinations. EI yielded similar concentrations of factor XIII a subunit in all the preparations tested. 3 functional assays showed high factor XIII activities in AHF-Kabi but low or no activities in the others. Thus, considerable differences were found on the in vitro properties of the proteins in 5 factor VIII concentrates and a cryoprecipitate. The action of proteases and the techniques used in the purification procedure are probably of crucial importance for the properties of the various factors.
Collapse
|
45
|
Abstract
Fanconi's anaemia and haemophilia A are born inherited diseases creating haemostatic defects. The association of these two rare diseases in one patient is described. The patient's haemophilia was studied with a newly developed immunological technique determining the plasma antigen associated with Factor VIII activity, and was found to be a genetic variant of moderately severe haemophilia A. It was not possible to demonstrate a common bone marrow defect or a common immunological or genetical background of the two diseases. The double haemostatic defect created, i.e. Factor VIII deficiency and thrombocytopenia, resulted in only a slight increase in bleeding tendency. A favourable result was obtained with corticosteroid and androgenic treatment.
Collapse
|